Clinical Trial Results:
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic
Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have
Disease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who are
Intolerant of Imatinib
Summary
|
|
EudraCT number |
2004-002601-69 |
Trial protocol |
AT DE SE FI GB IE IT BE ES DK |
Global completion date |
07 Jul 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA180-013_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.